[{"orgOrder":0,"company":"Avacta Group","sponsor":"Daewoong Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Licensing Agreement","leadProduct":"Mesenchymal stem cells","moa":"","graph1":"Immunology","graph2":"Undisclosed","graph3":"Avacta Group","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Avacta Group \/ Avacta Group","highestDevelopmentStatusID":"1","companyTruncated":"Avacta Group \/ Avacta Group"},{"orgOrder":0,"company":"Avacta Group","sponsor":"AffyXell Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Large molecule","year":"2020","type":"Collaboration","leadProduct":"Stefin A","moa":"","graph1":"Immunology","graph2":"Undisclosed","graph3":"Avacta Group","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Avacta Group \/ AffyXell Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Avacta Group \/ AffyXell Therapeutics"},{"orgOrder":0,"company":"Avacta Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Undisclosed","year":"2020","type":"Not Applicable","leadProduct":"SARS-COV-2 Neutralising Affimers","moa":"ACE2","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Avacta Group","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Avacta Group \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Avacta Group \/ Not Applicable"},{"orgOrder":0,"company":"Avacta Group","sponsor":"LG Chem","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Partnership","leadProduct":"AVA6000","moa":"PD-L1","graph1":"Oncology","graph2":"Preclinical","graph3":"Avacta Group","amount2":0.45000000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.45000000000000001,"dosageForm":"","sponsorNew":"Avacta Group \/ LG Chem Life Sciences","highestDevelopmentStatusID":"4","companyTruncated":"Avacta Group \/ LG Chem Life Sciences"},{"orgOrder":0,"company":"Avacta Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"FAP activated doxorubicin prodrug","moa":"PD-L1","graph1":"Oncology","graph2":"Preclinical","graph3":"Avacta Group","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Avacta Group \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Avacta Group \/ Not Applicable"},{"orgOrder":0,"company":"Avacta Group","sponsor":"Point Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Pro-doxorubicin","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Avacta Group","amount2":0.02,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"","sponsorNew":"Avacta Group \/ POINT Biopharma","highestDevelopmentStatusID":"4","companyTruncated":"Avacta Group \/ POINT Biopharma"},{"orgOrder":0,"company":"Avacta Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"FAP-Activated Doxorubicin prodrug","moa":"DNA topoisomerase II alpha","graph1":"Oncology","graph2":"Preclinical","graph3":"Avacta Group","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Avacta Group \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Avacta Group \/ Not Applicable"},{"orgOrder":0,"company":"Avacta Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"FAP Activated Doxorubicin Prodrug","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Avacta Group","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Avacta Group \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Avacta Group \/ Not Applicable"},{"orgOrder":0,"company":"Avacta Group","sponsor":"LG Chem","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Partnership","leadProduct":"PD-L1 XT","moa":"PD-L1","graph1":"Oncology","graph2":"Preclinical","graph3":"Avacta Group","amount2":0.45000000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.45000000000000001,"dosageForm":"","sponsorNew":"Avacta Group \/ LG Chem Life Sciences","highestDevelopmentStatusID":"4","companyTruncated":"Avacta Group \/ LG Chem Life Sciences"},{"orgOrder":0,"company":"Avacta Group","sponsor":"LG Chem","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Expanded Collaboration","leadProduct":"PD-L1 XT","moa":"PD-L1","graph1":"Oncology","graph2":"Preclinical","graph3":"Avacta Group","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Avacta Group \/ LG Chem","highestDevelopmentStatusID":"4","companyTruncated":"Avacta Group \/ LG Chem"},{"orgOrder":0,"company":"Avacta Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"FAP Activated Doxorubicin Prodrug","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I","graph3":"Avacta Group","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Avacta Group \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Avacta Group \/ Not Applicable"},{"orgOrder":0,"company":"Avacta Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Doxorubicin Prodrug","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I","graph3":"Avacta Group","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Avacta Group \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Avacta Group \/ Not Applicable"},{"orgOrder":0,"company":"Avacta Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"FAP Activated Doxorubicin Prodrug","moa":"PD-L1","graph1":"Oncology","graph2":"Preclinical","graph3":"Avacta Group","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Avacta Group \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Avacta Group \/ Not Applicable"},{"orgOrder":0,"company":"Avacta Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Doxorubicin Prodrug","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Avacta Group","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Avacta Group \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Avacta Group \/ Not Applicable"},{"orgOrder":0,"company":"Avacta Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"AVA3996","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Avacta Group","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Avacta Group \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Avacta Group \/ Not Applicable"},{"orgOrder":0,"company":"Avacta Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Doxorubicin Prodrug","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Avacta Group","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Avacta Group \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Avacta Group \/ Not Applicable"},{"orgOrder":0,"company":"Avacta Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Doxorubicin Prodrug","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Avacta Group","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Avacta Group \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Avacta Group \/ Not Applicable"},{"orgOrder":0,"company":"Avacta Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Doxorubicin Prodrug","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Avacta Group","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Avacta Group \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Avacta Group \/ Not Applicable"},{"orgOrder":0,"company":"Avacta Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Doxorubicin Prodrug","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Avacta Group","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Avacta Group \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Avacta Group \/ Not Applicable"},{"orgOrder":0,"company":"Avacta Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Doxorubicin Prodrug","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Avacta Group","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Avacta Group \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Avacta Group \/ Not Applicable"},{"orgOrder":0,"company":"Avacta Group","sponsor":"Tempus","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Peptide","year":"2024","type":"Collaboration","leadProduct":"AVA6103","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Avacta Group","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Avacta Group \/ Avacta Group","highestDevelopmentStatusID":"14","companyTruncated":"Avacta Group \/ Avacta Group"},{"orgOrder":0,"company":"Avacta Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Peptide","year":"2024","type":"Not Applicable","leadProduct":"AVA6103","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Avacta Group","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Avacta Group \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Avacta Group \/ Not Applicable"}]
Find Clinical Drug Pipeline Developments & Deals by Avacta Group
Details :
The collaboration will provide Avacta access to Tempus’ multimodal datasets to characterize the deep biology of the tumor microenvironment and FAP activity for AVA6103 and AVA7100.
Details :
AVA6103 is a Gen Two pre|CISION peptide drug conjugate, which is being evaluated for the treatment of gastric cancer, triple negative breast cancer & small cell lung cancer.
Details :
AVA6000 is a form of doxorubicin that has been chemically modified with Avacta’s pre|CISION platform designed to reduce systemic side effects by targeting the release of active chemotherapy in tumour tissue.
Details :
AVA6000 is a form of doxorubicin that has been chemically modified with Avacta’s pre|CISIONTM platform designed to reduce systemic side effects by targeting the release of active chemotherapy in tumour tissue.
Details :
AVA6000 is a novel form of doxorubicin, first-in-class FAPα activated prodrug that has been modified with Avacta’s pre|CISION™ FAP-activated delivery platform to improve its safety and therapeutic index.
Details :
AVA6000 is a novel form of doxorubicin (prodrug) that has been modified with Avacta’s pre|CISION™ FAP-activated delivery platform to improve its safety and therapeutic index.
Details :
AVA6000 is a novel form of doxorubicin (prodrug) that has been modified with Avacta’s pre|CISION™ FAP-activated delivery platform to improve its safety and therapeutic index.
Details :
AVA3996 is a tumour microenvironment activated proteasome inhibitor, a novel pre|CISION™ medicine, targeted to the tumor microenvironment via fibroblast activation protein-alpha (FAP-a) mediated cleavage.
Details :
AVA6000 is the first-in-class FAPα activated prodrug based on the pre|CISION platform, providing a prodrug form of doxorubicin with an improved safety profile enabling broader use in oncology, particularly in combinations with immuno-oncology drug agent...
Details :
AVA6000 is form of generic chemotherapy doxorubicin that has been modified using the pre|CISION technology so that it is activated predominantly in tumour with aim of sparing healthy tissue from exposure and improving the safety, tolerability and efficac...
Brand Name : AVA6000
Molecule Type : Large molecule
Upfront Cash : Not Applicable
September 05, 2022
Lead Product(s) :
FAP Activated Doxorubicin Prodrug
Reset All
